Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12865426 | 1.00 | MIF (0.40) | MIFCYP3A4NFKB1SMN1; SMN2CYP2C9 | |
| SCHEMBL9077491 | 1.00 | MIF (0.40) | MIFCYP3A4NFKB1SMN1; SMN2CYP2C9 | |
| SCHEMBL9078939 | 1.00 | MIF (0.40) | MIFCYP3A4NFKB1SMN1; SMN2CYP2C9 | |
| SCHEMBL8667692 | 0.85 | MAPT (0.40) | MIFNFKB1SMN1; SMN2NPC1RECQL | |
| SCHEMBL4091240 | 0.85 | MAPT (0.40) | MIFNFKB1SMN1; SMN2NPC1RECQL | |
| SCHEMBL4091245 | 0.85 | MAPT (0.40) | MIFNFKB1SMN1; SMN2NPC1RECQL | |
| SCHEMBL6992245 | 0.83 | NOS2 (0.49) | MIFRECQLMAPTLMNAALDH1A1 | |
| SCHEMBL7420415 | 0.83 | NOS2 (0.49) | MIFRECQLMAPTLMNAALDH1A1 | |
| SCHEMBL7420416 | 0.83 | NOS2 (0.49) | MIFRECQLMAPTLMNAALDH1A1 | |
| SCHEMBL6992247 | 0.83 | NOS2 (0.49) | MIFRECQLMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452974-B2 | Stereoselective synthesis of metyrosine | ATON PHARMA, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452974-B2 | Stereoselective synthesis of metyrosine | ATON PHARMA, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20140350284-A1 | STEREOSELECTIVE SYNTHESIS OF METYROSINE | JPMORGAN CHASE BANK, N.A. | 2014-11-27 | — | — | US | disclosed |
| US-20140350284-A1 | STEREOSELECTIVE SYNTHESIS OF METYROSINE | JPMORGAN CHASE BANK, N.A. | 2014-11-27 | — | — | US | disclosed |
| US-8841486-B2 | Stereoselective synthesis of metyrosine | ATON PHARMA (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841486-B2 | Stereoselective synthesis of metyrosine | ATON PHARMA (US) | 2014-09-23 | — | — | US | disclosed |
| US-20110104765-A1 | STEREOSELECTIVE SYNTHESIS OF METYROSINE | ATON PHARMA, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110104765-A1 | STEREOSELECTIVE SYNTHESIS OF METYROSINE | ATON PHARMA, INC. | 2011-05-05 | — | — | US | disclosed |
| US-5554753-A | Catalytic enantioselective synthesis of α-amino acid derivatives by phase-transfer catalysis | INDIANA UNIVERSITY FOUNDATION (US) | 1996-09-10 | — | — | US | disclosed |
| WO-1995006029-A1 | ENANTIOSELECTIVE SYNTHESIS OF ALPHA - ALKYLATED AMINO ACID DERIVATIVES BY PHASE - TRANSFER CATALYSIS | INDIANA UNIVERSITY FOUNDATION (US) | 1995-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104765-A1 | STEREOSELECTIVE SYNTHESIS OF METYROSINE | PTMA, PTMS, METTL3 | MIF 1786/4885CYP3A4 29/4885NFKB1 3596/4885 |
| US-20140350284-A1 | STEREOSELECTIVE SYNTHESIS OF METYROSINE | PTMA, PTMS, METTL3 | MIF 1786/4885CYP3A4 29/4885NFKB1 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.